Literature DB >> 6827092

Selectivity of angiotensin II antisera.

J Nussberger, G R Matsueda, R Re, E Haber.   

Abstract

A significant problem in the immunoassay of angiotensin II is the cross-reactivity of most available antisera with the peptide's metabolic products, (des-Asp1)-angiotensin II and (des-Asp1.Arg2)-angiotensin II. In order to attempt to generate antisera of greater selectivity, a variety of conjugates between angiotensin II or derivative peptides and carrier proteins were examined as immunogens with the aim of generating antisera that would selectively identify the amino terminal region of the peptide. Selectivity for the amino terminus was achieved by either (1) immunization with N-acetylated angiotensin II-amide which had been coupled to rabbit serum albumin by its carboxy terminus, or (2) immunization with angiotensin-(1-7)-heptapeptide which was randomly coupled to thyroglobulin. The antisera produced with the N-acetylated immunogen cross-reacted with the unacetylated ligand (Asn1-Val5)-angiotensin, but did not recognize the human hormone (Asp1,Ile5)-angiotensin. Carboxy-terminal coupling of angiotensin without N-acetylation did not induce selectivity for the amino terminus, nor did a conjugate which was linked to the carrier protein via a diazo bond to His6 of the peptide. These findings may be explained by the fact that N-acetylated angiotensin II resists degradation by amino peptidases and thus retains its structure in the immunogen and by the fact that the (1-7)-heptapeptide has lost the immunodominant carboxy-terminal epitope, thus emphasizing the desired amino terminal determinant.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6827092     DOI: 10.1016/0022-1759(83)90051-0

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  3 in total

Review 1.  An evolving story of angiotensin-II-forming pathways in rodents and humans.

Authors:  Carlos Maria Ferrario; Sarfaraz Ahmad; Sayaka Nagata; Stephen W Simington; Jasmina Varagic; Neal Kon; Louis Joseph Dell'italia
Journal:  Clin Sci (Lond)       Date:  2014-04       Impact factor: 6.124

2.  Epitope diversity of angiotensin II analysed with monoclonal antibodies.

Authors:  C Picard; P Ronco; P Moullier; J Yao; B Baudouin; M Geniteau Legendre; P Verroust
Journal:  Immunology       Date:  1986-01       Impact factor: 7.397

Review 3.  Cognizance of posttranslational modifications in vaccines: A way to enhanced immunogenicity.

Authors:  Rupal Ojha; Vijay Kumar Prajapati
Journal:  J Cell Physiol       Date:  2021-06-25       Impact factor: 6.513

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.